JP Morgan Maintains Overweight on Halozyme Therapeutics, Raises Price Target to $23

JP Morgan maintains Halozyme Therapeutics (NASDAQ:HALO) with a Overweight and raises the price target from $20 to $23.

Benzinga · 11/13/2019 13:24

JP Morgan maintains Halozyme Therapeutics (NASDAQ:HALO) with a Overweight and raises the price target from $20 to $23.